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Review Article
Glucocorticoid replacement therapy, available since the 1950s, has prolonged the survival of patients with adrenal insufficiency.1 How-ever, adrenal crises, which are life-threatening medical emergencies, still 
develop in many affected patients. Adrenal crisis appears to be increasing in fre-
quency, despite the availability of effective preventive strategies.2-4 This review exam-
ines the definitions, pathophysiology, epidemiology, and treatment of adrenal crises.
Defini tions of A dr ena l Cr isis
There is no universally accepted definition of an adrenal crisis, also called acute 
adrenal insufficiency or addisonian crisis.5 Generally, acute physiological distur-
bances in patients with known hypoadrenalism are labeled as adrenal crises on 
the basis of clinical assessment.2,5,6 Diagnostic misclassification may not alter im-
mediate management but, at the epidemiologic level, can impede an understand-
ing of the nature of adrenal crises.
Given the lack of a research-based classification and in recognition of the 
physiological changes that distinguish an adrenal crisis from a milder episode 
of hypoadrenalism,5-11 pragmatic definitions of adrenal crisis have generally 
been adopted.2,5,8,9 An adrenal crisis in an adult is defined as an acute deteriora-
tion in health status associated with absolute hypotension (systolic blood pressure 
<100 mm Hg) or relative hypotension (systolic blood pressure ≥20 mm Hg lower 
than usual), with features that resolve within 1 to 2 hours after parenteral gluco-
corticoid administration (i.e., a marked resolution of hypotension within 1 hour 
and improvement in clinical symptoms over a period of 2 hours).
Since identification of hypotension in infants and young children during an 
emergency may be difficult, an adrenal crisis in this age group is defined as an 
acute deterioration in health status associated with an acute hemodynamic distur-
bance (hypotension or sinus tachycardia relative to age-related normative data) or 
a marked electrolyte abnormality (e.g., hyponatremia, hyperkalemia, or hypoglyce-
mia not attributable to another illness). After parenteral glucocorticoid adminis-
tration, the features ascribed to adrenal crisis resolve substantially.12-16
Concomitant features in patients of all ages include acute abdominal symp-
toms; delirium, obtundation, or both; and hyponatremia, hyperkalemia, hypo-
glycemia, and pyrexia.5-11 When hypotension ascribed to an adrenal crisis does 
not respond or responds poorly to glucocorticoid administration, the coexistence of 
other illnesses associated with hypotension, such as sepsis, should be considered.
Adrenal crises are the most severe manifestation of adrenal insufficiency, but 
they share symptoms with milder hypoadrenal states. These symptoms include 
anorexia, nausea, vomiting, fatigue, postural dizziness, abdominal pain, limb and 
back pain, and impaired consciousness. Shared biochemical perturbations include 
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hyponatremia, hyperkalemia (in primary adrenal 
insufficiency [Addison’s disease and congenital 
adrenal hyperplasia]), and hypoglycemia (more 
common in children than in adults) (Table 1).5-8,11 
However, an acute illness in a patient who has 
previously received a diagnosis of primary adre-
nal insufficiency without evidence of hemody-
namic compromise or hypotension (or in young 
children, delayed capillary refill or tachycardia 
as alternative physical manifestations) should be 
considered physiologically distinct from an adre-
nal crisis and instead classified as symptomatic 
adrenal insufficiency, a precursor of adrenal 
crisis, or an incipient adrenal crisis.2,5,7,8 Marked 
symptoms in the absence of hypotension prob-
ably signal an incipient adrenal crisis, and treat-
ment with hydrocortisone and intravenous fluids 
may avert the development of an actual adrenal 
crisis.
Pathoph ysiol o gic a l Fe at ur es
Adrenal crises arise from an absolute or a rela-
tive deficiency of cortisol, an endogenous gluco-
corticoid; in that circumstance, there is insuf-
ficient tissue glucocorticoid activity to maintain 
homeostasis. The contributing pathophysiologi-
cal processes are depicted in Figure 1.
Cortisol has a circulating half-life of 90 min-
utes; hence, tissues become deficient within 
several hours after cortisol deprivation. Corti-
sol has highly pleiotropic effects that are due to 
transcriptional modulation of genes bearing a 
glucocorticoid response element (29% of all 
genes).17 The physiological consequences of cor-
tisol deficiency are extensive and start with loss 
of the normal suppressive action of endogenous 
glucocorticoids on inflammatory cytokines, re-
sulting in rapid increases in cytokine levels, 
which cause fever, malaise, anorexia, and bodily 
pain. Consequently, cortisol deficiency leads to 
altered immune-cell populations (neutropenia, 
eosinophilia, and lymphocytosis); loss of the syn-
ergistic action of cortisol with catecholamines 
on vascular reactivity, leading to vasodilatation 
and hypotension; hepatic effects on intermedi-
ary metabolism, with reduced gluconeogenesis, 
hypoglycemia, or both; and reduced circulating 
free fatty acids and amino acids.18-21
At the cellular level, loss of cortisol depresses 
the action of activator protein 1 (AP-1) and nuclear 
factor κB (NF-κB), leading to the unfettered acti-
vation of genes that produce inflammatory pro-
teins, since the normal cortisol inhibition of the 
binding of NF-κB to the glucocorticoid receptor 
is lost.17,18 Furthermore, mineralocorticoid defi-
ciency, which is prominent in primary but not 
secondary adrenal insufficiency,3,22,23 is likely to 
exacerbate adrenal crises through sodium and 
water loss and potassium retention.
Symptoms
Gastrointestinal: anorexia, nausea, vomiting
Pain: abdominal, limb, back
Severe fatigue
Severe weakness
Postural dizziness, syncope
Confusion
Signs
Abdominal tenderness or guarding
Hyperpigmentation (only in primary adrenal insufficiency)†
Pyrexia
Hypotension: systolic pressure <100 mm Hg in adults or 
≥20 mm Hg lower than usual in adults, acute hemo-
dynamic disturbance according to age-related norma-
tive levels in children, delayed capillary refill or tachy-
cardia in young children, circulatory collapse
Impaired consciousness: delirium, obtundation, coma
Biochemical abnormalities on routine blood tests
Hyponatremia
Hyperkalemia
Hypercalcemia
Hypoglycemia (more common in children than in adults)
Altered immune-cell populations: neutropenia,  
eosinophilia, lymphocytosis
Mild normocytic anemia
*  An adrenal crisis is defined as an acute deterioration in 
health status associated with hypotension (absolute or 
relative), with features that resolve within 1 to 2 hours 
 after parenteral glucocorticoid administration (i.e., a 
marked resolution of hypotension within 1 hour and im-
provement in clinical symptoms over a period of 2 hours). 
Since hypotension may be more difficult to identify in in-
fants and young children than in adults, an acute hemo-
dynamic disturbance, a marked abnormality in one or 
more electrolytes, or hypoglycemia not attributable to 
 another illness can be used for identification.
†  Hyperpigmentation develops slowly and can be a specific 
sign of undiagnosed primary adrenal insufficiency (Addi-
son’s disease or congenital adrenal hyperplasia) or of an 
insufficient dose of glucocorticoid replacement over a long 
period in a patient with primary adrenal insufficiency.
Table 1. Symptoms, Signs, and Biochemical 
Characteristics of Adrenal Crisis.*
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Epidemiol o gic Fe at ur es
Each year, approximately 6 to 8% of patients 
with adrenal insufficiency have an incident adre-
nal crisis.2,3 Adrenal crises are slightly more fre-
quent in patients with primary hypoadrenalism 
than in those with secondary adrenal insuffi-
ciency, probably because of partial preservation 
of cortisol secretion in some patients with second-
ary adrenal insufficiency,3 as well as the absence 
of mineralocorticoid secretion in those with pri-
mary hypoadrenalism.22-24 Adrenal crises are un-
common in patients with hypoadrenalism due to 
long-term glucocorticoid therapy, despite a vari-
able degree of consequent adrenal suppression.25
Susceptibility to adrenal crises varies among 
patients with hypoadrenalism. Risk factors in-
clude older age, a history of prior adrenal crises, 
the presence of autoimmune polyglandular syn-
dromes, type 1 diabetes mellitus, and nonendo-
crine coexisting conditions such as asthma and 
cardiac disease. However, the mechanism of ac-
tion of these various factors in adrenal crisis is 
unclear and may be specific to coexisting condi-
tions.22,23,26,27 In addition, unknown factors may 
potentiate the risk of adrenal crisis, since some 
patients have numerous episodes, whereas others 
have few, if any, episodes.28 An association be-
tween the occurrence of an adrenal crisis and 
the chronic asthenia that is characteristic of 
hypoadrenalism is plausible but not established. 
However, a recent prospective, multicenter study 
using questionnaires to obtain data from 110 pa-
tients with primary adrenal insufficiency showed 
a positive association between episodes of in-
cipient adrenal crisis and a poor quality of life.29
It has been suggested, on the basis of epide-
miologic data, that rising rates of adrenal crisis 
may be due to current use of lower-dose, short-
acting glucocorticoid regimens (hydrocortisone 
or cortisone acetate) in patients with hypoadre-
nalism.2,4,30,31 This hypothesis is supported by 
evidence from a longitudinal analysis involving 
156 patients with congenital adrenal hyperplasia 
who received care at a referral center. The study 
showed that a low baseline hydrocortisone re-
placement dose was associated with more fre-
quent episodes of various illnesses, requiring 
supplemental doses (“stress doses”) of glucocor-
ticoids.30
Morta li t y
Adrenal crises contribute to mortality among 
patients with hypoadrenalism23,28,32-36; the adre-
nal crisis–associated rate of death may reach 6% 
of crisis events.28 Adrenal crises may contribute to 
the increased mortality attributed to infectious 
disease among patients with hypoadrenalism.33 
Fatal adrenal crises have occurred in patients 
without a preceding diagnosis of hypoadrenal-
ism, although symptoms may have been over-
looked before the fatal episode.1,37-40
E v en t s Th at Pr ecipi tate 
A dr ena l Cr isis
Infections, which act as inflammatory stressors, 
commonly precipitate adrenal crises.2,3,22,26-28 Gas-
troenteritis is frequently cited as a precipitant 
and can be particularly hazardous, since vomit-
ing and diarrhea impair the absorption of oral 
medication and may also exacerbate dehydra-
tion. However, the abdominal symptoms of ad-
renal crisis may lead to an erroneous diagnosis 
of gastroenteritis.2,5,22 Bacterial infections pre-
dominate among infection-related precipitat-
ing events in older patients, whereas viral infec-
tions are more common precipitating events in 
children.12,22,27,28,41,42
Other pathophysiological states may precipi-
tate an adrenal crisis if the body cannot mount 
an increase in endogenous cortisol and if the 
amount of replacement therapy is not increased. 
Such conditions include serious injury and major 
surgery, but situations that generally are associ-
ated with the need for milder cortisol increases 
(exercise and emotional upset) have been reported 
as crisis precipitants in up to 10% of episodes, 
according to the results of patient surveys in which 
no specific precipitant was identified.3,22,24,27,28 
Adrenal crises have been reported in association 
with the release of acute-phase cytokines and 
other substances after certain relatively minor 
medical procedures such as vaccinations and 
zoledronic acid infusion.43,44
Some types of immunotherapy or chemother-
apy may precipitate adrenal crises. For example, 
immune-checkpoint inhibitor therapy, typically 
used in the treatment of melanoma and certain 
other cancers, may cause adrenal insufficiency 
n engl j med 381;9 nejm.org August 29, 2019 855
Adrenal Crisis
Figure 1. Pathophysiology of Adrenal Crisis.
Cortisol and aldosterone deficiency leads to an adrenal insufficiency syndrome as a result of effects on most of the body’s organs and 
tissues. Severe adrenal insufficiency, with hypotension (i.e., adrenal crisis), often develops at times of an increased cortisol requirement 
or physiological stress, leading to derangements of the physiological processes depicted. E denotes epinephrine, NE norepinephrine, 
and TNF-α tumor necrosis factor α.
Increased inflammatory
cytokines, sickness syndrome,
fever, and fatigue
Increased potassium
reabsorption
(hyperkalemia)Reduced sodium
reabsorption
Hyponatremia
Immune cells
TNF-α
Interleukin-1
Interleukin-6
Activation of cellular
inflammatory pathways
Impaired brain function,
delirium, and fatigue
Reduced production
of free fatty acids
Decreased
gluconeogenesis
Hypoglycemia
Vasodilatation, impaired
effect of catecholamines
Increased capillary
permeability
Reduced amino
acid liberation
Aldosterone
deficiency
Cortisol
deficiency
Zona
fasciculata
NE E 
Zona
glomerulosa
H
H
OHHO
H
O
O OH
n engl j med 381;9 nejm.org August 29, 2019856
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
(risk <1%) due to induction of hypophysitis (and 
pituitary hormone deficits) or adrenalitis.45 If 
these serious adverse events occur, prompt glu-
cocorticoid replacement is required.45,46
Nonadherence to glucocorticoid replacement 
therapy may also precipitate an adrenal crisis.22,28 
Patients need to be educated about the dangers 
of dose omission or cessation, particularly during 
a perioperative period and during long-term glu-
cocorticoid therapy for other illnesses in which 
the daily dose is higher than the replacement 
dose (3 to 5 mg of prednisone or the equivalent 
per day), since sudden discontinuation can act as 
a precipitant.22,47 Clinician-initiated abrupt cessa-
tion of glucocorticoid therapy has also been re-
ported as a cause of adrenal crisis.48
Undiagnosed coexisting thyrotoxicosis, or the 
initiation of thyroxine therapy in a patient with 
undiagnosed hypoadrenalism, may precipitate 
an adrenal crisis.2,49,50 Furthermore, cytochrome 
P-450 3A4 (CYP3A4) inducers such as avasimibe, 
carbamazepine, rifampicin, phenytoin, and St. 
John’s wort extract may increase hydrocortisone 
metabolism, necessitating an increase in the glu-
cocorticoid dose in patients being treated for 
adrenal insufficiency, or may induce an adrenal 
crisis in patients with undiagnosed adrenal in-
sufficiency.51 In contrast, CYP3A4 inhibitors such 
as voriconazole, grapefruit juice, itraconazole, 
ketoconazole, clarithromycin, lopinavir, nefazo-
done, posaconazole, ritonavir, saquinavir, telapre-
vir, telithromycin, and conivaptan may inhibit 
the metabolism of hydrocortisone, increasing 
cortisol levels and thereby enhancing the adre-
nal suppressive effect of ongoing glucocorticoid 
therapy,51,52 but the risk of adrenal crisis may be 
increased once the agent has been discontinued.
Tr e atmen t
Treatment of an adrenal crisis is effective if ad-
ministered promptly, before prolonged hypoten-
sion leads to irremediable effects.6,27,41 Treatment 
includes prompt administration of intravenous 
hydrocortisone, given as a 100-mg bolus, followed 
by 200 mg every 24 hours, administered as a 
continuous infusion or as frequent intravenous (or 
intramuscular) boluses (50 mg) every 6 hours, 
with subsequent doses tailored to the clinical 
response (Table 2). If hydrocortisone is unavail-
able, another parenteral glucocorticoid,7 such as 
dexamethasone (4 mg every 24 hours), methyl-
prednisolone (40 mg every 24 hours), or pred-
nisolone (25 mg as a bolus, followed by two 
25-mg doses, for a total of 75 mg in the first 24 
hours; thereafter, 50 mg every 24 hours), may be 
used. In children, hydrocortisone should be ad-
ministered as a parenteral bolus of 50 mg per 
square meter of body-surface area, followed by 
50 to 100 mg per square meter every 24 hours 
(administered as a continuous intravenous infu-
sion or as intravenous or intramuscular boluses 
every 6 hours). Hydrocortisone (cortisol) is the 
preferred drug for treatment of an adrenal crisis 
because of its physiological glucocorticoid phar-
macokinetics, plasma protein binding, tissue dis-
tribution, and balanced glucocorticoid–mineralo-
corticoid effects.
The doses suggested for prednisolone and 
dexamethasone are based on their glucocorti-
coid potency relative to hydrocortisone, in agree-
ment with current treatment guidelines for pri-
mary adrenal insufficiency.7 Fludrocortisone is not 
required if hydrocortisone doses exceed 50 mg 
given every 24 hours. As a practical matter, in 
patients with primary adrenal insufficiency, 
fludrocortisone therapy is usually resumed once 
the adrenal crisis has resolved and oral hydro-
cortisone replacement is feasible.
During an ongoing adrenal crisis in an adult, 
intravenous normal saline should be adminis-
tered (1000 ml within the first hour), with crys-
talloid fluids (e.g., 0.9% isotonic sodium chlo-
ride) given according to standard resuscitation 
guidelines and with adjustment for the patient’s 
circulatory status, body weight, and relevant co-
existing conditions.2,5,6 Intravenous dextrose 5% 
in normal saline is given for hypoglycemia (i.e., 
when the glucose values are less than 3.9 mmol 
per liter [70 mg per deciliter]). In children, a bolus 
of normal saline is given at a dose of 20 ml per 
kilogram of body weight, with repeated doses at 
up to 60 ml per kilogram the first hour. If there 
is hypoglycemia, dextrose at a dose of 0.5 to 1 g 
per kilogram is administered.
On rare occasions, patients have both adrenal 
insufficiency and diabetes insipidus, most often 
in those with lymphocytic hypophysitis. Fluids 
should be administered with caution in patients 
with diabetes insipidus, whether or not they are 
receiving treatment for it, since excessive free 
water may cause hyponatremia and too little may 
cause hypernatremia. Careful matching of urine 
output and normal saline infusion generally 
maintains isonatremia.2
Concomitant investigation and treatment of 
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the precipitating illness are required in all pa-
tients with adrenal crisis. Persistent shock de-
spite specific treatment for adrenal crisis sug-
gests another cause of hypotension.
After successful management of an adrenal 
crisis, hydrocortisone doses should be tapered, 
typically over a period of 3 days, to the patient’s 
usual maintenance dose. An assessment for pre-
ventable precipitating events should be made, 
and preventive strategies should be explained to 
the patient, including self-administration of par-
enteral hydrocortisone.2,6
M a nagemen t Issues
Health Care Milieu
Adrenal crisis prevention relies on responsive 
and informed health care professionals (ambu-
lance, nursing, and medical staff) and on effec-
tive patient education, so that the patient can 
initiate glucocorticoid dose escalation if needed. 
However, case reports (see the illustrative case in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org) and, more 
recently, systematic studies of the timeliness of 
the assistance provided by health care profes-
sionals have exposed a range of potential delays 
and difficulties that may affect the incidence 
and outcome of adrenal crisis.5,48,53 Some envi-
ronmental factors, such as the slow arrival of an 
ambulance, may be unavoidable but are never-
theless important to address.54 For example, en-
suring that ambulances have hydrocortisone 
available for injection, a policy adopted by emer-
gency services in some regions, may be very 
useful in the management of an adrenal crisis.
Of great concern are published reports of re-
fusal by medical staff to administer hydrocorti-
Treatment Dose and Procedure
Adults
Hydrocortisone* Provide prompt administration at a dose of 100 mg intravenously (or intramuscularly if intrave-
nous access is not feasible), followed by 200 mg every 24 hr, given as a continuous infusion or 
as intravenous (or intramuscular) boluses (50 mg) every 6 hr; if initial treatment is successful 
(usually after 24 hr), oral hydrocortisone at 2 to 3 times the usual dose can be given, with  
tapering down to the usual dose over the next 2 to 3 days†
Fluids Provide intravenous administration of 1000 ml of normal saline (0.9% isotonic sodium chloride) 
in the first hour, with intravenous dextrose to 5% concentration in normal saline added if the 
patient has hypoglycemia; subsequently, administer crystalloid fluids according to standard 
resuscitation guidelines‡
Children
Hydrocortisone Provide prompt administration at a dose of 50 mg per square meter of body-surface area intrave-
nously (or intramuscularly if intravenous access is not feasible), followed by 50–100 mg per 
square meter every 24 hr, given as a continuous infusion or as intravenous (or intramuscular) 
boluses (12.5–25 mg per square meter) every 6 hr; if initial treatment is successful (usually  
after 24 hr), oral hydrocortisone at 2 to 3 times the usual dose can be given, with tapering 
down to the usual dose over the next 2 to 3 days†
Fluids Give a bolus of normal saline at a dose of 20 ml per kilogram of body weight, with repeated doses 
up to a maximum of 60 ml per kilogram in the first hour, along with intravenous dextrose, 
0.5–1 g per kilogram, if the patient has hypoglycemia; provide subsequent administration  
of crystalloid fluids according to standard resuscitation guidelines‡
Adults and children
Possible additional  
measures
Antibiotic therapy, admission to intensive care or high-dependency unit, administration of low-
dose heparin
Prompt investigation of other causes when hypotension persists despite adequate initial  
treatment
Consideration of precipitating events (e.g., sepsis, gastroenteritis)
*  If hydrocortisone is unavailable, another parenteral glucocorticoid, such as dexamethasone (4 mg every 24 hours), 
methylprednisolone (40 mg every 24 hours), or prednisolone (25 mg bolus followed by two 25-mg doses, for a total  
of 75 mg in the first 24 hours; thereafter, 50 mg every 24 hours), may be used.
†  Fludrocortisone replacement is not required if hydrocortisone doses exceed 50 mg every 24 hours but is typically admin-
istered in adults and children with primary adrenal insufficiency when oral hydrocortisone is started.
‡  Circulatory status, body weight, and relevant coexisting conditions should be taken into account.
Table 2. Management of Adrenal Crisis.
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sone because of the mistaken belief that the 
adverse effects of glucocorticoids are greater than 
the risk of withholding hydrocortisone from an 
ill patient with hypoadrenalism.2,5,48,53,54 Indeed, 
recent evidence of unsatisfactory levels of knowl-
edge about adrenal insufficiency and adrenal 
crisis among various types of clinicians highlights 
the importance of continuing education.55-58
Hospital reviews of time-critical events in the 
treatment of patients with adrenal insufficiency, 
particularly the time to intravenous hydrocorti-
sone administration, can be used for quality-
assurance purposes and benchmarking.54,59 Audits 
of hospital treatment (inpatient admissions, ad-
missions to the intensive care unit [use of me-
chanical ventilation], adverse sequelae, and mor-
tality) may help ensure adequate outcomes. In the 
hospital, use of a “red flag” system to indicate 
hypoadrenalism should encourage the adminis-
tration of glucocorticoid replacement therapy and 
of appropriate doses of glucocorticoids for surgi-
cal procedures.25,58 On a national basis, regular 
evaluation of hospital admissions and data on 
pharmaceutical prescriptions can identify other 
problems, such as variations in the incidence of 
adrenal crises4,31,60 due to, among other issues, in-
terruption in the supply of glucocorticoid tablets.60
Patient Factors
Patients with hypoadrenalism often report dis-
satisfaction with medical care; reasons for their 
dissatisfaction include demanding glucocorticoid 
replacement schedules, a delay in the initial diag-
nosis, post-treatment impairment of well-being 
(in up to 40% of patients), and adrenal crisis–
related anxiety.26,54,61-67 Functional impairment in 
patients with adrenal insufficiency, manifested by 
fatigue and by reduced participation in work ow-
ing to sick leave and disability,68 may be related 
to noncircadian69 or nonindividualized glucocor-
ticoid replacement. Moreover, there is a marked 
interindividual variation in hydrocortisone phar-
macokinetics,70 and hydrocortisone treatment af-
fects mental and physical health through altered 
tryptophan metabolism.71 Furthermore, reduced 
quality of life may lead to an elevated risk of 
adrenal crisis among those most severely affected.29
Pr e v en tion
Key strategies that can prevent adrenal crisis 
include an individualized prescription and plan 
for the use of supplementary glucocorticoid ad-
ministration for physiological stress; use of par-
enteral hydrocortisone, preferably at home, when 
oral glucocorticoids cannot be taken; and the 
provision of devices, such as a MedicAlert brace-
let or necklace (discussed below), that can warn 
caregivers of the risk of adrenal crisis when pa-
tients cannot communicate verbally.
Oral stress dosing of glucocorticoids, designed 
to replicate the cortisol stress response, involves 
doubling or tripling the replacement dose, de-
pending on the intensity of the stress (e.g., a dou-
ble dose for a lower fever [temperature <38.5°C] 
and a triple dose for a higher fever [temperature 
≥38.5°C]), until the illness has abated. Stress 
dosing is based on mimicking the physiological 
response to illness, but oral hydrocortisone phar-
macokinetics are highly variable, and patients 
with rapid metabolism may have a less marked 
response to modest dose manipulations than 
patients with slower metabolism.70 Higher doses, 
administered parenterally, may be needed in 
cases of severe stress such as major surgery 
and may perhaps reach maximal adrenal secre-
tory output (approximately 200 mg of hydro-
cortisone every 24 hours [8.5 times the normal 
output], as used in intervention studies of septic 
shock).72-74
In patients with vomiting or diarrhea, paren-
teral hydrocortisone (100 mg in adults) is recom-
mended.2,5,6 Patients and their family members 
should be taught how to perform intramuscular 
injection of hydrocortisone and should be pro-
vided with vials, needles, and syringes.2,5,12 Omis-
sion of stress dosing may result in progression 
to adrenal crisis and may contribute to the ob-
served lack of efficacy of current preventive 
measures.41,48 Parenteral administration of hydro-
cortisone at home may prevent progression of an 
early adrenal crisis.3,5
However, injectable hydrocortisone is not of-
fered to, or may not be obtained by, all pa-
tients.54,57 Barriers to hydrocortisone use by 
patients include reluctance to inject the drug 
intramuscularly,26,41 impaired dexterity,48 and ad-
vanced age.26 Subcutaneous administration of 
hydrocortisone is an alternative to the intramus-
cular route, and although this is an off-label 
method of administration, it may be more ac-
ceptable to patients.2,75 Pharmacokinetic data 
indicate that subcutaneous and intramuscular 
injections in nonobese patients with adrenal 
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insufficiency, albeit without shock, have similar 
effects.75 Rectal hydrocortisone suppositories may 
be an alternative in some circumstances.
Measures that enhance communication may 
be simple but are important. For example a “ste-
roid card,” MedicAlert card, or the equivalent 
(Fig. S1 in the Supplementary Appendix) and a 
subscription service that uses medical jewelry 
inscribed with a patient’s diagnosis and linked 
by an identification number to a call center for 
further information are recommended.76,77 Non-
use of these measures is common,57,77 but use 
may be improved through patient education.77
Despite efforts directed at encouraging pa-
tients to manage their glucocorticoid treatment 
in order to prevent adrenal crises, only some pa-
tients initiate dose escalation effectively.41,48,57,78 
Outcomes from intensive patient education 
programs are disappointing and contribute to 
the persistent or increasing rates of adrenal 
crises.4,31,79
R educing the Incidence  
of A dr ena l Cr ises
Available Approaches
Broader application of preventive strategies may 
decrease the incidence of adrenal crises, and 
prompt domiciliary and health service–based 
treatment may lessen their severity and sequelae. 
Pre-emergency injection of intramuscular or off-
label subcutaneous hydrocortisone may avert 
many episodes of adrenal crisis. Formal regula-
tory approval for subcutaneous hydrocortisone 
may increase its home use.
Future Approaches
A preloaded hydrocortisone syringe, similar to the 
epinephrine autoinjector, has been recommended2 
but is not yet generally available. It may be pos-
sible to devise other products or routes for hydro-
cortisone administration that are simpler for 
patients to use in emergencies, such as an intra-
nasal or inhaled spray or powder. Ultimately, 
alternative delivery systems for adrenal hormone 
replacement such as a “bioartificial adrenal cor-
tex,” as a cell-based solution, are appealing. Such 
constructs may use adrenal allogeneic or xeno-
geneic cells in an implanted container such as an 
alginate capsule; alternatively, a method in which 
the cells can evade the patient’s immune system 
may become feasible. If successful, these ap-
proaches will improve the quality of life for pa-
tients with adrenal insufficiency and eliminate 
adrenal crises.80,81
Summ a r y
Adrenal crises are life-threatening episodes of 
adrenal insufficiency, which continue to occur 
despite preventive interventions. Patient educa-
tion in the use of oral stress dosing, parenteral 
hydrocortisone administration when required, 
and communication devices to inform health 
care workers of the risk of adrenal crisis and 
required treatment are the current approaches to 
preventing adrenal crises. New solutions to this 
persistent problem are needed.
No potential conflict of interest relevant to this article was 
reported.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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